Gregory J. Robitaille is Director at Neos Therapeutics, Inc. (NEOS). They have made 1 open-market trade across 1 company since 2016, most recently 2021-03-19.
CIK 0001238910
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $112K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NEOS | 79,130 | $91K |
Shares reported on the most recent Form 4, priced at the 2020-06-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NEOS | BUY | 2016-05-18 | 2016-05-19 | $7.55 | $112K | +40.7% | +25.2% | -10.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.